Literature DB >> 26020713

Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study.

Maya Amitai1, Ephi Sachs, Amir Zivony, Roei Remez, Reut Ben Baruch, Ben H Amit, Sefi Kronenberg, Alan Apter, Gal Shoval, Abraham Weizman, Gil Zalsman.   

Abstract

The objective of this study was to determine the long-term hematological and biochemical side effects of valproic acid (VPA) in psychiatric adolescent inpatients. A retrospective naturalistic study design was used. Participants were psychiatric inpatients treated with VPA, alone or in combination with other medications. Electronic medical files were reviewed for changes in hematological and biochemical parameters following a course of VPA treatment. One hundred and four adolescents aged 12-18 (mean 15.76±1.58) years fulfilled the study criteria. The mean blood level and duration of VPA treatment were 65.81±22.18 mcg/ml and 98.57±135.94 days, respectively. The mean levels of thyroid-stimulating hormones and triglyceride levels increased significantly from the first to the last measurement. Platelet count decreased significantly following VPA treatment. No correlation was observed between these parameters and age, duration of treatment, or VPA levels. No serious adverse events were reported. Long-term VPA treatment in adolescents with psychiatric disorders is associated with significant increases in triglyceride levels. Moreover, VPA-treated adolescent psychiatric inpatients may be at risk of developing pituitary-thyroid axis dysregulation and decreased platelet count. Therefore, baseline measurement of thyroid functions and metabolic and hematological parameters and monitoring throughout the treatment are recommended.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26020713     DOI: 10.1097/YIC.0000000000000084

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  6 in total

1.  Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma.

Authors:  M V Bais
Journal:  J Dent Res       Date:  2019-01-07       Impact factor: 6.116

Review 2.  Variation of the prevalence of pediatric polypharmacy: A scoping review.

Authors:  Courtney Baker; James A Feinstein; Xuan Ma; Shari Bolen; Neal V Dawson; Negar Golchin; Alexis Horace; Lawrence C Kleinman; Sharon B Meropol; Elia M Pestana Knight; Almut G Winterstein; Paul M Bakaki
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-06       Impact factor: 2.890

Review 3.  Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.

Authors:  Rosanne W Meijboom; Koen P Grootens
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

4.  Outcome measures in pediatric polypharmacy research: a scoping review.

Authors:  Negar Golchin; Hannah Johnson; Paul M Bakaki; Neal Dawson; Elia M Pestana Knight; Sharon B Meropol; Rujia Liu; James A Feinstein; Shari D Bolen; Lawrence C Kleinman; Alexis Horace
Journal:  Drugs Ther Perspect       Date:  2019-07-12

Review 5.  Parkinsonism: A Rare Adverse Effect of Valproic Acid.

Authors:  Abilash Muralidharan; Jawaria Rahman; Dipanjan Banerjee; Abdul Rub Hakim Mohammed; Bilal Haider Malik
Journal:  Cureus       Date:  2020-06-23

6.  Epigenetic drugs: from chemistry via biology to medicine and back.

Authors:  Lucia Altucci; Marianne G Rots
Journal:  Clin Epigenetics       Date:  2016-05-23       Impact factor: 6.551

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.